BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum
Summary
- The FDA accepted BridgeBio Pharma, Inc.'s NDA regulatory submission of Acoramidis for the treatment of patients with ATTR-CM and set a PDUFA date of November 29th of 2024.
- Partnership established with Bayer to commercialize Acoramidis for the treatment of patients with ATTR-CM in European territories; Regulatory approval for Europe expected in 2025.
- The transthyretin amyloidosis treatment market size is expected to reach $11.2 billion by 2032.
- In August 2024, the company is expected to provide a program update for the use of BBP-631 for the treatment of patients with congenital adrenal hyperplasia.
- Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »
Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.
He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.
Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.